Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tudorza

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

GSK’s Anoro backed in Europe for COPD

CHMP recommendation set to expand pharma company’s respiratory portfolio

- PMLiVE

GSK’s Anoro first LAMA/LABA approved for COPD in US

Important step towards eventually replacing Seretide/Advair sales

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

- PMLiVE

FDA guidance clears path for Advair generics

Offers simplified process for potential copies of GSK’s asthma and COPD drug

- PMLiVE

FDA queries safety of GSK’s Anoro for COPD

Adviser questions the drug's cardiovascular profile

- PMLiVE

Forest and Almirall delay FDA filing of COPD drug

Puts companies behind in LAMA/ LABA combination race

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

AstraZeneca boosts R&D prospects with Pearl acquisition

Deal to acquire respiratory firm could be worth up to $1.15bn

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links